Western tradition · Mitochondrial-targeted antioxidant
A mitochondria-targeted antioxidant with small but real placebo-controlled trials showing improved vascular function in older adults — the evidence base is thinner and more concentrated in one research group than CoQ10's.
Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.
Not a traditional remedy: MitoQ is an engineered analog of CoQ10 (a triphenylphosphonium-conjugated ubiquinone) designed to concentrate antioxidant activity inside mitochondria, since standard CoQ10 poorly penetrates the mitochondrial membrane.
Key active: Mitoquinone mesylate (mitochondria-targeted ubiquinone).
By selectively accumulating in mitochondria, MitoQ aims to neutralize the reactive oxygen species implicated in age-related vascular dysfunction; small placebo-controlled trials (roughly 20–60 participants, mostly from one research group) at 20 mg/day for 6 weeks to 3 months show improved flow-mediated dilation and reduced arterial stiffness in healthy older and vascularly-impaired adults, but the evidence base is narrower — fewer independent labs, smaller samples — than established mitochondrial-support compounds like CoQ10, and no trial tests hard clinical or longevity endpoints.
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| Flow-mediated dilation (endothelial function, older adults) — Placebo-controlled but small samples (n≈20–60), largely from one research group | Increases | Moderate | B |
| Arterial stiffness (pulse wave velocity, elevated baseline) | Decreases | Minor | B |
| Oxidized LDL (oxidative stress marker) | Decreases | Minor | C |
| Hard cardiovascular events / lifespan | No change | Negligible | D |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
Generally well-tolerated in trials at 20 mg/day. Independent replication outside the primary research group is limited — treat the vascular-function results as promising but not yet broadly confirmed.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Small human RCTs (mostly one research group) for vascular function; no hard clinical or longevity endpoints
By selectively accumulating in mitochondria, MitoQ aims to neutralize the reactive oxygen species implicated in age-related vascular dysfunction; small placebo-controlled trials (roughly 20–60 participants, mostly from one research group) at 20 mg/day for 6 weeks to 3 months show improved flow-mediated dilation and reduced arterial stiffness in healthy older and vascularly-impaired adults, but the evidence base is narrower — fewer independent labs, smaller samples — than established mitochondrial-support compounds like CoQ10, and no trial tests hard clinical or longevity endpoints.
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-07-19. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Suppliers
Tell us what you need and we will source suppliers for you.